Ivermectin + Fenbendazole Stack: The Combination Protocol Taking Reddit, Telegram and Podcasts by Storm in 2025

Mel Gibson sat across from Joe Rogan in January 2025 and casually mentioned three friends — all diagnosed with stage IV cancer — who no longer had any detectable cancer. All three had taken ivermectin and fenbendazole together. That single podcast segment accumulated over 11.5 million views. Within days, searches for the ivermectin fenbendazole stack exploded globally. Moreover, oncologists across America began reporting that between 20% and 25% of their cancer patients were quietly taking one or both drugs without telling their care teams.

This guide covers what this combination actually is, why researchers believe the two drugs work better together than alone, what the 2025 and 2026 evidence shows, how to run the stack correctly, and where to source both safely in the USA.

---

Why These Two Drugs Together?

Ivermectin and fenbendazole belong to different drug classes. Yet both target several of the same core vulnerabilities in cancer cells. This overlap — plus their complementary differences — is precisely why researchers and patients began stacking them.

Fenbendazole is a benzimidazole antiparasitic that disrupts microtubules, blocks glucose uptake, and reactivates the p53 tumor suppressor gene. Ivermectin, meanwhile, targets completely different pathways. According to a comprehensive review published in PMC (National Library of Medicine), ivermectin inhibits cancer cell proliferation by regulating multiple signaling pathways including PAK1 kinase, STAT3, Wnt/β-catenin, and AKT/mTOR. Additionally, ivermectin promotes programmed cancer cell death through apoptosis, autophagy, and pyroptosis — three distinct self-destruction mechanisms that cancer cells work hard to avoid. The same review confirms that ivermectin also targets cancer stem cells, which is significant because cancer stem cells drive recurrence and resistance to conventional therapy.

Together, therefore, these two drugs attack cancer biology from more angles simultaneously than either one can achieve alone. This is the core logic behind the stack — not redundancy, but genuine multi-target complementarity.

---

The Mel Gibson Moment and Why It Went Viral

The January 2025 Joe Rogan podcast episode featuring Mel Gibson became the single most impactful media event for this combination protocol. Gibson’s account of three separate friends recovering from stage IV cancer using ivermectin and fenbendazole together was anecdotal. Nevertheless, it reached an audience of millions who were already hungry for alternatives.

According to Oncology News Central, the story spread so fast that practicing oncologist Dr. Samyukta Mullangi at Tennessee Oncology began seeing the combination inquiry in her clinic almost immediately. “This has spread like wildfire,” she stated publicly in June 2025. Furthermore, a colleague estimated that 20–25% of his cancer patients were already taking these drugs. This is not a fringe movement anymore. It is a mainstream patient behavior that oncologists are actively grappling with.

---

What the 2025–2026 Research Actually Shows

The first-of-its-kind peer-reviewed protocol combining ivermectin, fenbendazole, and mebendazole was officially published on September 19, 2024, spearheaded by researchers including Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC’s Dr. Paul Marik. That publication marked the transition from patient community knowledge to formal medical literature.

Subsequently, a January 2026 systematic review analyzed 457 case reports from social media, patient testimonials, and clinical communications collected between 2023 and 2025. The cancer types most commonly represented were breast cancer (especially triple-negative), pancreatic, lung, prostate, and colorectal. Several documented cases stand out clearly:

A 66-year-old woman from California with stage IV breast cancer ran the triple combination after discontinuing conventional treatment. Her CA15-3 tumor marker declined, and her PET scan showed tumor reduction alongside complete resolution of liver metastases.

A 43-year-old woman from Argentina with unresectable pancreatic cancer added mebendazole to her ivermectin and fenbendazole stack. After eleven months, her contrast CT scan showed a pancreas appearing normal with no anomalies.

A stage IV endometrial cancer patient in Canada saw peritoneal metastasis shrink approximately 60% over just two months on the ivermectin-fenbendazole combination.

Importantly, the 2026 review also notes selection bias — self-reported successes are overrepresented, 68% of cases involved concurrent therapies, and no control arm existed. Consequently, these cases cannot prove causality. However, they do justify the urgent call for properly designed clinical trials.

On the clinical trial front, a Phase I/II study from Cedars-Sinai Medical Center (Yuan et al, presented at ASCO 2025) evaluated ivermectin combined with balstilimab immunotherapy in metastatic triple-negative breast cancer patients. Of eight evaluable patients, one achieved partial response and one had stable disease. Critics note the response rate was not significantly better than immunotherapy alone. Supporters counter that the trial was tiny, heavily pre-treated, and used dosing protocols not yet optimized for combination use. Either way, this represents meaningful institutional progress — Cedars-Sinai running the trial at all signals that the combination deserves serious investigation.

---

How the Stack Works: Complementary Mechanisms Explained Simply

Think of cancer as a fortress with multiple walls. Fenbendazole attacks three walls — the structural scaffolding (microtubules), the energy supply (glucose), and the alarm system (p53 reactivation). Ivermectin, however, scales entirely different walls — it disrupts the command-and-control signaling networks (STAT3, Wnt, AKT/mTOR), eliminates the fortress’s ability to repair and rebuild (autophagy induction), and specifically targets the fortress architects who would rebuild it after any attack (cancer stem cells).

Furthermore, a January 2026 review published on OneDayMD notes that preclinical models suggest schedule-dependent synergy between benzimidazoles and ivermectin — meaning the timing and sequencing of doses may matter as much as the doses themselves. Ongoing research is working to identify the optimal scheduling for maximum combined effect.

---

The Full Stack Protocol: Dosages and Schedule

The following protocol reflects current community practice based on documented patient reports and integrative physician guidance. Always consult a qualified healthcare provider before starting.

Fenbendazole: 222mg to 444mg daily, taken three days on and four days off each week. Take with a high-fat food — eggs, coconut oil, or avocado — to significantly improve absorption. Increase gradually in 222mg increments based on tolerance. Some patients and practitioners have moved to 500mg to 1000mg daily doses for more aggressive protocols.

Ivermectin: Dosed at 1mg per kilogram of body weight daily, also cycling three days on and four days off. Alternatively, some protocols use a fixed dose of 12mg to 24mg daily depending on body weight. Take on an empty stomach with water, at least one hour before food.

Vitamin E succinate: 400 to 800 IU daily. This specific form — not standard tocopherol — enhances fenbendazole bioavailability and carries its own independent anti-tumor mechanisms identified in multiple preclinical studies.

Bioavailable curcumin: 600mg daily with a piperine or liposomal formulation. Standard curcumin absorbs poorly on its own. Moreover, curcumin supports p53 restoration and adds meaningful anti-inflammatory, anti-tumor activity to the stack.

CBD oil (full spectrum): 25mg sublingual daily. Research indicates CBD may increase the bioavailability of both fenbendazole and hydroxychloroquine when taken concurrently. Additionally, it independently modulates tumor growth pathways.

Berberine: 1000 to 1500mg daily in divided doses before meals. Berberine amplifies fenbendazole’s glucose-blocking effect through a complementary pathway, further cutting the energy supply to cancer cells.

---

The Non-Negotiable Safety Layer

Both ivermectin and fenbendazole process through the liver. Running both simultaneously therefore demands careful monitoring. Anyone following this stack must obtain a comprehensive metabolic panel (CMP) within the first month, then every two to four weeks thereafter.

Watch ALT and AST liver enzymes specifically. If either rises significantly above baseline, reduce or pause the doses immediately. A 2021 case report in Case Reports in Oncology documented drug-induced liver injury in a lung cancer patient who self-administered fenbendazole without monitoring. That case underscores why blood work is essential — not optional.

Beyond liver monitoring, disclose both medications to any treating physician or oncologist. Ivermectin interacts with blood thinners including warfarin. Furthermore, P-glycoprotein inhibitors can raise ivermectin plasma levels substantially. Similarly, fenbendazole may theoretically interact with some chemotherapy agents through shared metabolic pathways. These interactions require professional assessment based on your individual medication list.

---

Sourcing Both Safely in the USA

Product quality determines everything with this stack. Counterfeit and substandard products flood online marketplaces. A 2024 laboratory analysis of fenbendazole products sold on Amazon found certain batches testing at only 56% purity. The remaining content was sodium carbonate filler — a substance that damages kidneys with prolonged exposure.

For fenbendazole, always demand a third-party Certificate of Analysis confirming active content, purity percentage, and batch number. Pharmaceutical-grade fenbendazole in 222mg, 444mg, 500mg, and 1000mg tablets is available through licensed online pharmacies serving the US market.

For ivermectin 12mg, residents of Tennessee, Arkansas, Idaho, and Louisiana can purchase it over the counter today. Residents of all other states can legally obtain it through telehealth — a licensed US physician evaluates your case online and issues a valid prescription, often within 24 hours. That prescription then fills through any licensed online pharmacy shipping to your state.

Never purchase either medication from social media sellers, Telegram groups promoting no-COA products, or websites offering prescription drugs without requiring a prescription. The cost savings are not worth the risk.

---

What Honest Practitioners Are Saying

The Anticancer Fund, one of Europe’s leading drug repurposing research organizations, addressed the ivermectin-fenbendazole combination directly in 2025. Their position is measured: early laboratory findings suggest potential anticancer effects, but rigorous human clinical trials are still missing. They specifically caution against abandoning evidence-based cancer treatment in favor of these protocols.

At the same time, integrative practitioners point to the compounds’ extraordinary safety profiles at therapeutic doses, their low cost compared to oncology drugs, and the growing body of preclinical data as justification for at least exploring them alongside — not instead of — standard care. Between 20% and 25% of cancer patients in some oncology practices are already using them quietly. Bringing that conversation into the clinic, with proper monitoring and professional oversight, is clearly safer than patients self-managing alone.

---

Frequently Asked Questions

Why do ivermectin and fenbendazole work better as a stack than separately? Each drug targets different cancer pathways. Fenbendazole disrupts microtubules, blocks glucose, and reactivates p53. Ivermectin disrupts oncogenic signaling networks, promotes three types of cell death, and eliminates cancer stem cells. Together, they attack more of cancer’s survival mechanisms simultaneously — reducing the ability of resistant cells to adapt and escape.

What is the standard ivermectin fenbendazole stack dose? The most commonly referenced combination is fenbendazole 222 to 444mg plus ivermectin 12 to 24mg (or 1mg/kg), both taken on a three days on, four days off cycle. Always take fenbendazole with fatty food and ivermectin on an empty stomach.

Can I run this stack alongside chemotherapy? Many patients do. However, this requires direct discussion with your oncologist because both drugs affect liver enzymes and may interact with specific chemotherapy agents. Regular blood work becomes even more critical when combining this stack with active cancer treatment.

Has any formal clinical trial proven the stack works in humans? Not yet. The ASCO 2025 Phase I/II trial at Cedars-Sinai evaluated ivermectin with immunotherapy in eight patients — too small to draw conclusions. A first-of-its-kind peer-reviewed protocol paper was published in September 2024, and the January 2026 systematic review analyzed 457 patient cases. Formal randomized controlled trials are still pending.

Where is the safest place to buy ivermectin 12mg and fenbendazole together in the USA? Use a licensed online pharmacy that requires a valid prescription for ivermectin and provides a Certificate of Analysis for fenbendazole. Telehealth services make obtaining the ivermectin prescription fast and legal from any US state.

---

Disclaimer: This article is for informational purposes only. Neither ivermectin nor fenbendazole is FDA-approved for cancer treatment in humans. Always consult a qualified oncologist or healthcare professional before starting any off-label medication protocol, particularly alongside existing cancer treatments.